The Other Side of Possible…

What does OSOP mean to us?

Learn About
Our Research Platform

What Drives Us?

The many friends and family of Agios employees affected by cancer are what motivates, inspires and drives us.

Melissa McLaughlin
SVP Human Resources

Our Research Focus

Cancer Metabolism

Inhibit key enzymes in cancer cell specific metabolic pathways to disrupt tumor cell proliferation and survival

Rare Genetic Diseases

Restore defective metabolic pathways in disease cells that cause rare genetic disorders of metabolism

Metabolic
Immuno-Oncology

Alter the metabolic state of immune cells to enhance the body’s anti-tumor response

Boldly Pursuing Excellence and Innovation

We are a research-driven organization focused on creating transformative medicines by combining expertise in metabolism and precision medicine.

research platform

The Spirit of Agios

The Spirit of Agios

At Agios, our culture and values are embodied in the Greek word Arete, the ancient ideal of excellence and fulfillment of one’s potential to which our employees aspire. Together, we are driven by a boundless passion for our work, and we pride ourselves on fostering an interconnected environment that encourages creative scientific collaboration across disciplines.

explore agios’ culture explore agios’ values

Passion for Discovery

our pipeline

Agios has leveraged its core capabilities in cellular metabolism and precision medicine to build a product engine that is focused in the therapeutic areas of cancer and rare genetic diseases.


CANDIDATE

Drug Discovery
Early Stage Clinical Development
Late Stage Clinical Development
Regulatory Submission

APPROVED
R/R AML
 
 
Phase 3 IDHENTIFY Ongoing
 
U.S.
IC Eligible Frontline AML
 
Phase 1b Combo Ongoing
IC Ineligible Frontline AML
 
Phase 1/2 Combo Ongoing
  • Celgene has worldwide development and commercialization rights.Agios has U.S. co –promotion and royalty rights.
R/R AML
 
Phase 1 Dose Escalation & Expansion Ongoing
 
U.S.
IC Eligible Frontline AML
 
Phase 1b Combo Ongoing
IC Ineligible Frontline AML
 
Phase 1/2 Combo Ongoing
Phase 3 AGILE Ongoing
Cholangio
 
 
Phase 3 ClarlDHy Ongoing
Glioma
 
Perioperative Study Ongoing
Glioma
 
Perioperative Study Ongoing

Joint worldwide collaboration with Celgene.   

MTAP-Deleted Tumors
 
Phase 1 Dose-Escalation Ongoing

The safety and efficacy of the agents and uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated.

Recent News & Events

04/11/2018

Agios to Webcast Investor Day and First Quarter 2018 Financial Results on Friday, May 4, 2018
read more

03/19/2018

Agios Announces First Patient Dosed with MAT2A Inhibitor AG-270 in Phase 1 Study in Patients with Advanced Solid Tumors or Lymphoma with an MTAP Deletion
read more

03/05/2018

Agios to Present at the Cowen 38th Annual Healthcare Conference Monday, March 12, 2018
read more

02/15/2018

FDA Accepts New Drug Application and Grants Priority Review for Ivosidenib in Relapsed or Refractory AML with an IDH1 Mutation
read more

Agios has a dynamic culture that supports our employees’ unwavering commitment to science and patients.

career opportunities